Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VistaGen Therapeutics (VTGN) stock

Learn how to easily invest in VistaGen Therapeutics stock.

VistaGen Therapeutics, Inc
NASDAQ: VTGN - USD
BIOTECHNOLOGY
$2.72
-$0.02 (-0.73%)

VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 21 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in VistaGen Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VTGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

VistaGen Therapeutics stock price (NASDAQ: VTGN)

Use our graph to track the performance of VTGN stocks over time.

VistaGen Therapeutics shares at a glance

Information last updated 2021-07-22.
Latest market close$2.63
52-week range$0.56 - $3.55
50-day moving average $2.86
200-day moving average $2.42
Wall St. target price$6.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.83

Buy VistaGen Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VistaGen Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VistaGen Therapeutics price performance over time

Historical closes compared with the close of $2.63 from 2021-05-26

1 week (2021-07-17) N/A
1 month (2021-06-28) -7.39%
3 months (2021-04-28) 7.79%
6 months (2021-01-24) N/A
1 year (2020-07-24) N/A
2 years (2019-07-24) N/A
3 years (2018-07-24) N/A
5 years (2016-07-24) N/A

VistaGen Therapeutics financials

Revenue TTM $1.1 million
Gross profit TTM $1.1 million
Return on assets TTM -19.66%
Return on equity TTM -36.78%
Profit margin 0%
Book value $0.51
Market capitalisation $556.9 million

TTM: trailing 12 months

Shorting VistaGen Therapeutics shares

There are currently 12.3 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 88.5% up from 6.5 million last month.

There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.

VistaGen Therapeutics's "short interest ratio" (SIR)

VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 3.2 million). VistaGen Therapeutics's SIR currently stands at 3.83. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 3830 shares are currently held short.

However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.081% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 81 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.

Find out more about how you can short VistaGen Therapeutics stock.

VistaGen Therapeutics share dividends

We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.

Have VistaGen Therapeutics's shares ever split?

VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.

VistaGen Therapeutics share price volatility

Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.5551 up to $3.55. A popular way to gauge a stock's volatility is its "beta".

VTGN.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.8923. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).

VistaGen Therapeutics overview

VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license and option agreements with Pherin Pharmaceuticals, Inc.

Stocks similar to VistaGen Therapeutics

Frequently asked questions

What percentage of VistaGen Therapeutics is owned by insiders or institutions?
Currently 0.227% of VistaGen Therapeutics shares are held by insiders and 60.734% by institutions.
How many people work for VistaGen Therapeutics?
Latest data suggests 21 work at VistaGen Therapeutics.
When does the fiscal year end for VistaGen Therapeutics?
VistaGen Therapeutics's fiscal year ends in March.
Where is VistaGen Therapeutics based?
VistaGen Therapeutics's address is: 343 Allerton Avenue, South San Francisco, CA, United States, 94080
What is VistaGen Therapeutics's ISIN number?
VistaGen Therapeutics's international securities identification number is: US92840H2022
What is VistaGen Therapeutics's CUSIP number?
VistaGen Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92840H103

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site